Midgard Science

Eviogen Discovery Private Limited

Bengaluru, India eviogen.com

From their website, Nov 2026

Work here? Claim this listing

About

Eviogen Discovery Private Limited is a contract research organization in Bangalore, India. It provides integrated drug discovery, biology, chemistry, DMPK, antibody, cell line, and protein services for pharma, biotech, life-science, and research organizations. It supports projects from target discovery and validation through lead selection and pre-clinical to clinical stages.

Services

  • Discovery biology

    Integrated drug discovery and screening support including target identification, target validation, in-vitro and in-vivo model development, ADMET, pharmacology, toxicology, and protein expression/purification.

    Assays & in vitro testing

  • Assay biology (in vitro)

    Cell-free and cell-based assay services against different therapeutic target classes for target validation and mechanism studies.

    Assays & in vitro testing

  • DMPK

    In vitro ADME and DMPK services including metabolism, permeability, transporters, solubility, physicochemical properties, protein binding, PK, and bioanalysis.

    ADME, DMPK & toxicology

  • In vitro ADMET

    Screening assays covering solution properties, drug absorption and transport, metabolic stability and identification, drug-drug interactions, and in vitro toxicity.

    ADME, DMPK & toxicology

  • Custom antibody development

    Polyclonal and monoclonal antibody development, purification, labeling, and single B-cell cloning and lead antibody identification.

    Assays & in vitro testing

  • Clone development and stable cell line generation

    Mammalian clone development and stable cell line generation for recombinant proteins, biosimilars, and novel biologics, including characterization and scale-up.

    Cell line development

  • Discovery chemistry

    Integrated chemistry, biology, and analytical support for compound design, synthesis, testing, PROTAC chemistry, SAR generation, and lead optimization.

  • Integrated drug discovery services

    Provides integrated drug discovery support from target discovery to lead candidate selection, with flexible FFS or FTE business models.

  • Assay biology

    Offers assay biology services using multiple assay platforms and model systems.

    Assays & in vitro testing

  • Small molecule discovery

    Supports discovery programs for small-molecule therapeutics.

  • PROTAC discovery

    Supports discovery programs for PROTAC therapeutics.

  • Screening services

    Provides high-throughput and high-content screening support.

    Assays & in vitro testing

  • Biologics services

    Supports biologics discovery programs.

  • PK & immunogenicity

    Provides pharmacokinetic and immunogenicity services.

    ADME, DMPK & toxicology

  • CAR-T & iPSC services

    Supports programs involving CAR-T and iPSC model systems.

  • CRISPR-Cas9 services

    Supports CRISPR-Cas9-based work.

  • Antibody drug conjugate services

    Supports antibody-drug conjugate discovery programs.

  • SPR analysis

    Offers surface plasmon resonance analysis using Biacore.

    Assays & in vitro testing

  • Antibody hybridoma services

    Provides hybridoma-related antibody services.

  • Sequencing services

    Offers next-generation sequencing services.

  • DMPK services

    Provides DMPK support including in vitro ADME and in vivo PK.

    ADME, DMPK & toxicology

  • Protein expression and purification

    Expresses and purifies proteins.

  • Cosmetic claim studies

    Conducts cosmetic claim studies.

    Assays & in vitro testing

Turnaround
Lead candidates identified within 4 weeks · Phase I - Immunization & Titer Evaluation (6-9 weeks) · Phase II - Hybridoma Generation & Screening (8-10 weeks) · Phase III - Subcloning & Characterization (3-5 weeks) · Phase IV - Production & Cryopreservation (3-4 weeks)
What to send
Polyclonal antibody development: minimum 5 mg of antigen at ≥0.5 mg/mL concentration · Antigen affinity chromatography requires antigen

Capabilities

Assays and studies
In vivo · Antibodies · ADME · SPR · ADCs · Cell therapy · High-content imaging · CRISPR · Hybridoma · Immunogenicity · Cell-free assays · Cell-based assays
17 moreTarget validation · Mechanism studies · In vitro metabolism · In vitro permeability · Transporter assays · Solubility · Physicochemical properties · Protein binding · Bioanalysis · PK/PD · Enzyme inhibition · CYP induction · Luminescence · TR-FRET/HTRF · Fluorescence polarization · Absorbance · AlphaLISA
Scale and capacity
Cryopreservation of up to 20 clones per month · Scaled antibody production (50-100 mL) · From shake flasks to 2,000L bioreactors · Target Gene to Master Cell Bank in 6 months · DNA to production clone under 30 weeks
Therapeutic areas
Inflammation · Oncology · Immuno-oncology · Metabolic diseases · Fibrosis · Autoimmune disorder · Infection

Instruments and platforms

  • SPR (Biacore)
  • WES Protein Simple
  • AlphaLISA
  • AlphaScreen
  • TR-FRET
  • HTRF
  • NanoBRET
  • High Content Imaging
  • Flow Cytometry
  • Next Generation Sequencing
  • Biacore

Modalities and species

Modalities
Small molecule · Antibody · ADC · Peptide · Cell therapy · Gene editing · Recombinant protein · Biosimilar
Species and models
Rabbit · Chicken · Mouse · CHO · HEK293 · PBMCs · Patient derived primary cells · iPSCs · Immortalized primary cell line · Reporter cell lines · Recombinant protein · Transient/stable cell line
3 moreMammalian cell lines · Animal/human PBMCs · Immune cells isolated from PBMCs

Industries served

  • Pharma
  • Biotech
  • Life-science
  • Research organizations
  • Biopharma
  • Pharmaceutical

Company

Type
CRO
Founded
2016
Quality
CPCSEA (animal procedures for monoclonal antibody production) · WHO (documentation aligned with cell line generation) · ICH (documentation aligned with cell line generation) · CDSCO (documentation aligned with cell line generation)

Locations

Based in
Bengaluru, India
Sites
Bangalore, India
Serves
global

Contacts

Similar labs

Work here? Claim this listing